Date: 2015-03-03
Type of information: Private placement
Company: Amag Pharmaceuticals (USA - MA)
Investors:
Amount: $ 201 million (€ 179.8 million)
Funding type: private placement
Planned used: Amag intends to use the net proceeds from this offering for general corporate purposes, including to continue the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies.
Others: * On March 3, 2015, Amag Pharmaceuticals announced the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 596,590 shares of common stock at the public offering price of $44.00 per share. The exercise of the underwriters\' option brought the total number of shares of common stock sold by AMAG to 4,573,862 and increased the total gross proceeds raised in the offering to approximately $201.2 million, before deducting underwriting discounts, commissions and estimated expenses. * On February 25, 2015, Amag Pharmaceuticals announced that it has priced its previously announced underwritten public offering of common stock consisting of 3,977,272 shares at a public offering price of $44.00 per share. Gross proceeds to Amag from this offering are expected to be approximately $175 million. Amag has granted the underwriters a 30-day option to purchase up to an additional 596,590 shares of common stock offered in the public offering. All of the shares in the offering will be sold by AMAG. The offering is expected to close on March 3, 2015, subject to customary closing conditions. * On February 24, 2015, Amag Pharmaceuticals announced that it has commenced an underwritten public offering of approximately $125 million of shares of its common stock. Amag intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock offered in the public offering. All of the shares in the offering will be sold by Amag. J.P. Morgan and Deutsche Bank Securities are acting as joint book-running managers for the offering. The offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area:
